

AMENDMENTS TO THE CLAIMS

Claim Listing:

1-8. (canceled)

9. (currently amended) A method for reducing undesirable toxic hepatotoxic side effects inherent in the anti-tumor therapy with Ecteinascidin 743 (ET-743) which comprises administering a cruciferous indole compound indole-3-carbinol or one or more derivatives or pharmaceutically acceptable salts thereof to a patient, wherein the indole-3-carbinol derivatives are selected from: 5-methyl-indole-3-carbinol, 5-ethyl-indole-3-carbinol, 5-propyl-indole-3-carbinol, 5-butyl-indole-3-carbinol, 5-pentyl-indole-3-carbinol, 5-methoxy-indole-3-carbinol, 5-ethoxy-indole-3-carbinol, 5-propyloxy-indole-3-carbinol, 5-butyloxy-indole-3-carbinol, 5-amyoxy-indole-3-carbinol, N-methyl-indole-3-carbinol, N-ethyl-indole-3-carbinol, N-propyl-indole-3-carbinol, N-butyl-indole-3-carbinol, N-pentyl-indole-3-carbinol, 2-methyl-indole-3-carbinol, 2-ethyl-indole-3-carbinol, 2-propyl-indole-3-carbinol, 2-butyl-indole-3-carbinol and 2-pentyl-indole-3-carbinol.

10. (currently amended) A method for an effective treatment of a tumour by combination therapy, employing in said combination therapy comprising administering an effective antitumor amount of ET-743 in combination with a cruciferous indole compound indole-3-carbinol or one or more derivatives or pharmaceutically acceptable salts thereof, wherein the indole-3-carbinol derivatives are selected from:

5-methyl-indole-3-carbinol, 5-ethyl-indole-3-carbinol, 5-propyl-indole-3-carbinol, 5-butyl-indole-3-carbinol, 5-pentyl-indole-3-carbinol, 5-methoxy-indole-3-carbinol, 5-ethoxy-indole-3-carbinol, 5-propyloxy-indole-3-carbinol, 5-butyloxy-indole-3-carbinol, 5-amyoxy-indole-3-carbinol, N-methyl-indole-3-carbinol, N-ethyl-indole-3-carbinol, N-propyl-indole-3-carbinol, N-

butyl-indole-3-carbinol, N-pentyl-indole-3-carbinol, 2-methyl-indole-3-carbinol, 2-ethyl-indole-3-carbinol, 2-propyl-indole-3-carbinol, 2-butyl-indole-3-carbinol and 2-pentyl-indole-3-carbinol.

11. (currently amended) A method according to claim 9 or 10, wherein the indole-3-carbinol or one or more derivatives or pharmaceutically acceptable salts thereof ~~eruciferous indole compound~~ is administered to a patient ~~who is going to be treated prior to treatment~~ with ET-743.

12. (currently amended) The method according to claim 9 or 10, wherein the indole-3-carbinol or one or more derivatives or pharmaceutically acceptable salts thereof ~~eruciferous indole compound~~ and ET-743 form part of the same medicament.

13. (currently amended) The method according to claim 9 or 10, wherein the indole-3-carbinol or one or more derivatives or pharmaceutically acceptable salts thereof ~~eruciferous indole compound~~ and ET-743 form part of separate medicaments.

14. (currently amended) The method according to ~~any of claims 9 to 13~~ claim 9 or 10, wherein the indole-3-carbinol or one or more derivatives or pharmaceutically acceptable salts thereof ~~eruciferous indole compound~~ is indole-3-carbinol.

15. (currently amended) The method according to ~~any of claims 9 to 14~~ claim 9 or 10, wherein the ~~combination therapy method~~ further ~~employs another~~ comprises administering an additional hepatoprotector.

16. (currently amended) The method according to claim 15, wherein the ~~other~~ additional hepatoprotector is dexamethasone.

17. (currently amended) The method according to ~~any claims 9 to 16~~ claim 9 or 10, wherein the patient has a cancer selected from sarcoma, osteosarcoma, ovarian cancer, breast cancer, NSCL carcinoma, melanoma, head and neck cancer, colorectal cancer, mesothelioma, renal cancer, endometrial cancer and lung cancer.

18. (currently amended) A composition for the treatment of cancer, which comprises ET-743 and ~~a cruciferous indole compound~~ indole-3-carbinol or one or more derivatives or pharmaceutically acceptable salts thereof, wherein the indole-3-carbinol derivatives are selected from: 5-methyl-indole-3-carbinol, 5-ethyl-indole-3-carbinol, 5-propyl-indole-3-carbinol, 5-butyl-indole-3-carbinol, 5-pentyl-indole-3-carbinol, 5-methoxy-indole-3-carbinol, 5-ethoxy-indole-3-carbinol, 5-propyloxy-indole-3-carbinol, 5-butyloxy-indole-3-carbinol, 5-amyoxy-indole-3-carbinol, N-methyl-indole-3-carbinol, N-ethyl-indole-3-carbinol, N-propyl-indole-3-carbinol, N-butyl-indole-3-carbinol, N-pentyl-indole-3-carbinol, 2-methyl-indole-3-carbinol, 2-ethyl-indole-3-carbinol, 2-propyl-indole-3-carbinol, 2-butyl-indole-3-carbinol and 2-pentyl-indole-3-carbinol.

19. (currently amended) The composition according to claim 18, wherein the ~~cruciferous indole compound~~ indole-3-carbinol or one or more derivatives or pharmaceutically acceptable salts thereof is indole-3-carbinol.

20. (new) The composition according to claim 18, wherein the indole-3-carbinol or one or more derivatives or pharmaceutically acceptable salts thereof is indole-3-carbinol or pharmaceutically acceptable salts thereof.

21. (new) The method according to claim 9 or 10, wherein the indole-3-carbinol or derivatives or pharmaceutically acceptable salts thereof is selected from indole-3-carbinol or pharmaceutically acceptable salts thereof.